Despite current clinical treatments for diabetic kidney disease (DKD) that aim to alleviate kidney damage by addressing direct and indirect metabolic and hemodynamic factors, such as using SGLT2 inhibitors to improve proteinuria and eGFR in patients with CKD25, our study cannot attribute albuminuria reduction to these drugs. This evidence concerns the gene SLC5A2 and diabetic kidney disease.